suggests that multidisciplinary therapy including an immunological approach might be a 7 breakthrough to refractory disease. 
Introduction

1
Breast cancer can metastasize to lymph node, bone, lung, liver, and brain. Lung 2 metastasis from breast cancer may not only decrease quality of life (QOL) but also 3 threaten the patient's life. Therefore, it is important to control it. 4 Like endocrine therapy for estrogen-receptor (ER)-positive breast cancer, 5 trastuzumab-based therapy is considered initially for tumors with overexpression of the 6 HER-2/neu protein or amplification of the her-2/neu gene, which occur in 20-25% of 7 metastatic breast cancers [1] . Treatment with trastuzumab, a humanized mAb directed 8 against the extracellular domain of HER2, resulted in a response rate of 21% in patients 9 pretreated with chemotherapy, as a single agent. Trastuzumab also increased the clinical 10 benefit of chemotherapy in metastatic breast cancer with HER2 overexpression [2] .
11
Furthermore, adjuvant use of trastuzumab reduced recurrence remarkably in primary 12 breast cancer [3] [4] .
13
The activity of trastuzumab was found to depend on the engagement of release of cytotoxic, granzyme-containing granules [8, 9] . Therefore, if we could 1 increase the activity of NK cells, the efficacy of treatment with trastuzumab could be 2 increased.
3
In this report, we present a case with refractory pulmonary metastasis, in which the 4 tumor was successfully treated with trastuzumab, taxane, capecitabine, and activated 5 NK cell injection therapy. two-week intervals.
10
We also measured cytotoxic activity of NK cells by the following method. Freshly for 2 hours and again checked for fluorescence intensity.
1
NK cell activity in the patient was extremely low before injection of activated NK 2 cells (Fig. 1) ; however, the activity increased after therapy began. Simultaneously, we decreased for six months, but began to increase following trastuzumab treatment. We 6 added capecitabine to trastuzumab; however, these tumor markers continued to increase.
7
At the same time, skin and bone metastases emerged. Therefore, weekly intravenous 8 injection of paclitaxel was added, and we also started hyperthermia for the skin (Fig. 1) . NK cell activity remained at a high level and the progression-free 12 survival was about 10 months. 
Discussion
16
In the current report, lung metastasis which had been refractory to anti-HER2 therapy 17 responded to the combination therapy of trastuzumab, capecitabine, paclitaxel, and An epidemiological study demonstrated that the natural cytotoxic activity of PBMCs 8 was significantly associated with reduced cancer risk [11] . We recently reported that NK 9 cell activity in metastatic breast cancer patients was significantly reduced compared 10 with that of healthy controls [12] . Furthermore, several exploratory studies have shown 11 that NK cell therapy contributes to reduce the tumor burden in human cancers [13] . 
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